Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

Eli Lilly recently reported detailed late-phase trial results showing that people with obesity were able to maintain long-term weight loss after switching to oral Foundayo or lower-dose Zepbound, ...

Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Eli Lilly saw a huge gain after its recent earnings report, but the wins didn't stop there Lilly also recently ...

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...

Eli Lilly (NYSE:LLY) just delivered one of the most impressive quarters in big pharma history, and the stock is responding.

Discover how Eli Lilly is increasing medical weight loss access in Indiana through Zepbound vials. Learn how this Indy innovation supports long-term health. By combining lower pricing, ...

Ro said it will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug ...

Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus ...

Eli Lilly (NYSE: LLY) has become the leader in a market marching toward the $100 billion mark. I'm talking about the ...

Federal ethics disclosures published recently show President Donald Trump’s accounts purchased Eli Lilly stock on at least seven occasions in the first quarter of 2026 — a period in which his ...

Feb 18 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed better results in patients with the skin disease and ...